Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2404112 | Vaccine | 2010 | 6 Pages |
Abstract
Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Linda R. Ojo, Rosalyn E. O’Loughlin, Adam L. Cohen, Jennifer D. Loo, Karen M. Edmond, Sharmila S. Shetty, Allyson P. Bear, Lois Privor-Dumm, Ulla K. Griffiths, Rana Hajjeh,